BR112014000535A2 - Composição farmacêutica contendo carreador de oxigênio termicamente estável para aplicações em diferentes tratamentos - Google Patents

Composição farmacêutica contendo carreador de oxigênio termicamente estável para aplicações em diferentes tratamentos

Info

Publication number
BR112014000535A2
BR112014000535A2 BR112014000535A BR112014000535A BR112014000535A2 BR 112014000535 A2 BR112014000535 A2 BR 112014000535A2 BR 112014000535 A BR112014000535 A BR 112014000535A BR 112014000535 A BR112014000535 A BR 112014000535A BR 112014000535 A2 BR112014000535 A2 BR 112014000535A2
Authority
BR
Brazil
Prior art keywords
cancer
tetrameric hemoglobin
thermally stable
hemoglobin
pharmaceutical composition
Prior art date
Application number
BR112014000535A
Other languages
English (en)
Inventor
Bing Lou Wong
Sui Yi Kwok
Sze Hang Lau
Original Assignee
Bing Lou Wong
Sui Yi Kwok
Sze Hang Lau
Billion King International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47506871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014000535(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bing Lou Wong, Sui Yi Kwok, Sze Hang Lau, Billion King International Ltd filed Critical Bing Lou Wong
Publication of BR112014000535A2 publication Critical patent/BR112014000535A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIÇÃO FARMACÊUTICA NÃO POLIMÉRICA, ALTAMENTE PURIFICADA E CONTENDO UM CARREADOR DE OXIGÊNIO TERMICAMENTE ESTÁVEL PARA APLICAÇÕES EM DIFERENTES TRATAMENTOS. A hemoglobina tetramérica reticulada não polimérica altamente purificada e termicamente estável adequada para uso em mamíferos sem causa vasoconstrição e lesão renal é fornecida. Uma etapa de processamento térmico em alta temperatura e curto tempo (HTST) é executada para remover eficazmente a indesejada forma dimérica de hemoglobina, hemoglobina tetramérica não reticulada e impureza de proteínas do plasma. Adição de N-acetilcisteína após o tratamento térmico e, opcionalmente, antes do tratamento térmico mantém um baixo nível de metahemoglobina. A hemoglobina tetramérica reticulada termicamente estável pode melhorar e prolongar a oxigenação no tecido normal e hipóxico. Em outro aspecto, o produto é usado no tratamento de vários tipos de câncer, tais como leucemia, câncer colorretal, câncer de pulmão, câncer de mama, câncer de figado, carcinoma nasofaríngeo e câncer de esôfago. A hemoglobina tetramérica inventiva também pode ser usada para prevenir recorrências após excisão cirúrgica do tumor e metástases de tumor. Aina mais a hemoglobina tetramérica inventiva pode ser administrada a pacientes antes do tratamento de quimioterapia e radioterapia.
BR112014000535A 2011-07-11 2012-07-11 Composição farmacêutica contendo carreador de oxigênio termicamente estável para aplicações em diferentes tratamentos BR112014000535A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/179,590 US8048856B1 (en) 2010-06-23 2011-07-11 Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
PCT/US2012/046130 WO2013009790A2 (en) 2011-07-11 2012-07-11 A heat stable oxygen carrier-containing pharmaceutical composition for different treatment applications

Publications (1)

Publication Number Publication Date
BR112014000535A2 true BR112014000535A2 (pt) 2017-10-03

Family

ID=47506871

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014000535A BR112014000535A2 (pt) 2011-07-11 2012-07-11 Composição farmacêutica contendo carreador de oxigênio termicamente estável para aplicações em diferentes tratamentos

Country Status (17)

Country Link
US (1) US8048856B1 (pt)
EP (1) EP2731619A4 (pt)
JP (1) JP6100252B2 (pt)
KR (1) KR101925346B1 (pt)
CN (1) CN103687609B (pt)
AP (1) AP3840A (pt)
AU (1) AU2012282692B2 (pt)
BR (1) BR112014000535A2 (pt)
CA (1) CA2841445C (pt)
CL (1) CL2014000053A1 (pt)
EA (1) EA201400020A1 (pt)
HK (1) HK1192714A1 (pt)
MA (1) MA35279B1 (pt)
MX (1) MX346736B (pt)
MY (1) MY169908A (pt)
WO (1) WO2013009790A2 (pt)
ZA (1) ZA201400698B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2849448C (en) 2011-09-06 2020-03-24 Bing Lou Wong Oral delivery for hemoglobin based oxygen carriers
US20140106004A1 (en) * 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
MA38571B1 (fr) * 2013-05-13 2018-10-31 Vision Global Holdings Ltd Composition pharmaceutique comprenant un agent thérapeutique à base d'hémoglobine modifiée pour un traitement de ciblage du cancer et imagerie diagnostique
US9225652B2 (en) * 2013-12-05 2015-12-29 Huawei Technologies Co., Ltd. Framework for traffic engineering in software defined networking
US9814759B2 (en) 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
US9763889B2 (en) 2015-06-29 2017-09-19 Billion King International Ltd. Oral delivery system for hemoglobin based oxygen carriers
US10052290B2 (en) 2016-02-04 2018-08-21 Billion King International Ltd. Enteric-coated hemoglobin multiparticulate for oral delivery of hemoglobin based oxygen carriers

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2548671B1 (fr) 1983-07-07 1986-05-02 Merieux Inst Procede de preparation de globine a partir d'hemoglobine et globine obtenue par ce procede
US4831012A (en) 1984-03-23 1989-05-16 Baxter International Inc. Purified hemoglobin solutions and method for making same
USRE34271E (en) 1984-06-27 1993-06-01 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4598064A (en) 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4600531A (en) 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
JPH0750329B2 (ja) 1986-06-23 1995-05-31 富士写真フイルム株式会社 画像形成材料
US5084558A (en) 1987-10-13 1992-01-28 Biopure Corporation Extra pure semi-synthetic blood substitute
CA1312009C (en) 1986-11-10 1992-12-29 Carl W. Rausch Extra pure semi-synthetic blood substitute
US5955581A (en) 1986-11-10 1999-09-21 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5753616A (en) 1986-11-10 1998-05-19 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5189146A (en) 1987-05-05 1993-02-23 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Pasteurizable, freeze-driable hemoglobin-based blood substitute
US5439882A (en) 1989-12-29 1995-08-08 Texas Tech University Health Sciences Center Blood substitute
US5344393A (en) 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US6187744B1 (en) 1992-03-11 2001-02-13 Michael W. Rooney Methods and compositions for regulating the intravascular flow and oxygenating activity of hemoglobin in a human or animal subject
US5387672A (en) * 1993-03-02 1995-02-07 The University Of Maryland At Baltimore Hemoglobin intramolecularly cross-linked withlong chain divalent reagents
US5840851A (en) 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
US5804561A (en) 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
TW381022B (en) 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5824781A (en) 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5817632A (en) 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5807831A (en) 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5725839A (en) 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5767089A (en) 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5840701A (en) 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5741893A (en) 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5631219A (en) 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
WO1995031727A1 (en) 1994-05-13 1995-11-23 Therasorb Medizinische Systeme Gmbh Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood
SE9500724D0 (sv) 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US6610832B1 (en) 1995-03-23 2003-08-26 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US5895810A (en) 1995-03-23 1999-04-20 Biopure Corporation Stable polymerized hemoglobin and use thereof
US6288027B1 (en) 1995-03-23 2001-09-11 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US5865784A (en) 1995-06-07 1999-02-02 Alliance Pharmaceutical Corp. Method of hemodilution facilitated by monitoring oxygenation status
US5691453A (en) 1995-06-07 1997-11-25 Biopure Corporation Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC
AU1083497A (en) 1995-11-30 1997-06-19 Somatogen, Inc. Method for control of functionality during cross-linking of hemoglobins
ATE247152T1 (de) 1996-03-21 2003-08-15 Kobusch Sengewald Gmbh & Co Kg Mehrlagenfolie, verfahren zu ihrer herstellung und ihre verwendung
WO1997039761A1 (en) 1996-04-19 1997-10-30 Alpha Therapeutic Corporation A process for viral inactivation of lyophilized blood proteins
US5814601A (en) 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
ATE302019T1 (de) 1997-02-28 2005-09-15 Univ California Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen
DE69826521T2 (de) 1998-01-06 2005-09-29 Cerus Corp., Concord Verfahren zum quenchen von pathogen-inaktivatoren in biologischen materialien
US6977140B1 (en) 1998-09-29 2005-12-20 Organ Recovery Systems, Inc. Method for maintaining and/or restoring viability of organs
US6894150B1 (en) 1999-10-01 2005-05-17 Ross Walden Tye Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin
DE10031744A1 (de) * 2000-06-29 2002-01-17 Sanguibio Tech Ag Mit Blutplasma verträgliche, vernetzte und mit Polyalkylenoxiden konjugierte Säugetierhämoglobine als künstliche medizinische Sauerstoffträger, ihre Herstellung und ihre Verwendung
US6747132B2 (en) 2000-11-29 2004-06-08 Apex Biosciences, Inc. Methods for the synthesis of a modified hemoglobin solution
JP4260417B2 (ja) 2001-05-23 2009-04-30 ノバルティス アクチエンゲゼルシャフト 溶液を輸送し脱酸素するためのシステム及び方法
US7038016B2 (en) 2001-08-21 2006-05-02 Apex Bioscience, Inc. Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution
US20050164915A1 (en) 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
BR0317721A (pt) 2002-12-23 2005-12-06 Einstein Coll Med Molécula de hemoglobina modificada e processo para fabricação da mesma
MXPA05007885A (es) 2003-01-29 2005-09-21 Northfield Lab Soluciones de hemoglobina polimerizada que tienen cantidad reducida de tetramero y metodo para prepararlas.
PL1838355T3 (pl) 2004-10-29 2014-01-31 Cerus Corp Ulepszone sposoby wygaszania dla procesu inaktywacji czerwonych krwinek
US7759306B2 (en) 2006-05-16 2010-07-20 Simoni Jan S Methods of treating acute blood loss
US7504377B2 (en) 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
US7494974B2 (en) 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
NZ581957A (en) 2007-06-13 2012-04-27 Opk Biotech Llc Targeted oxygen delivery via intravenous or intra-arterial infusion of oxygenated polymerized hemoglobin solutions
US7989593B1 (en) * 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US20110319332A1 (en) * 2010-06-23 2011-12-29 Bing Lou Wong Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US7932356B1 (en) 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition

Also Published As

Publication number Publication date
MX2014000355A (es) 2015-01-27
CN103687609B (zh) 2016-07-20
KR20140054038A (ko) 2014-05-08
HK1192714A1 (zh) 2014-08-29
WO2013009790A2 (en) 2013-01-17
CA2841445C (en) 2019-02-26
MX346736B (es) 2017-03-30
MA35279B1 (fr) 2014-07-03
AU2012282692A1 (en) 2014-01-30
KR101925346B1 (ko) 2018-12-05
JP6100252B2 (ja) 2017-03-22
AU2012282692B2 (en) 2017-04-27
NZ619782A (en) 2016-09-30
US8048856B1 (en) 2011-11-01
EP2731619A2 (en) 2014-05-21
MY169908A (en) 2019-06-14
CN103687609A (zh) 2014-03-26
CA2841445A1 (en) 2013-01-17
JP2014520850A (ja) 2014-08-25
CL2014000053A1 (es) 2014-08-29
EA201400020A1 (ru) 2014-06-30
WO2013009790A3 (en) 2013-04-04
EP2731619A4 (en) 2015-03-11
AP3840A (en) 2016-09-30
AP2014007422A0 (en) 2014-02-28
ZA201400698B (en) 2015-09-30

Similar Documents

Publication Publication Date Title
BR112014000535A2 (pt) Composição farmacêutica contendo carreador de oxigênio termicamente estável para aplicações em diferentes tratamentos
BR112012000617B8 (pt) método para a preparação de uma composição farmacêutica contendo veículo de oxigênio estável de calor
EA201101155A1 (ru) Способ приготовления фармацевтической композиции, содержащей теплостойкий переносчик кислорода
CY1121038T1 (el) Θεραπεια καρκινου μαστου
BR112016011949A8 (pt) composto, composição farmacêutica, e, uso dos mesmos”
MX2016007311A (es) Metodos para tratar canceres.
AR078588A1 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
MX359989B (es) Fármacos antivirales para el tratamiento de la infección por arenavirus.
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
RU2014117666A (ru) Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами атr
MY163300A (en) Method for the preparation of a heat stable oxygen carrier-containing composition facilitating beta-beta cross-linking
EA201490472A1 (ru) Комбинированная терапия рака hsp90-ингибитором и антиметаболитом
BR112015010019A8 (pt) benzimidazóis tricíclicos substituídos como inibidores de cinase
MX2014011583A (es) Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
BR112014009365A2 (pt) método para inibição da atividade de deubiquitinação
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
EA201590546A1 (ru) Способы лечения заболеваний, связанных с волосами
BR112015005392A2 (pt) formulação de comprimido de um inibidor de fosfatidilinositol 3-cinase
EA201500579A1 (ru) Комбинированная терапия с использованием воласертиба
TH77663B (th) วิธีการสำหรับการเตรียมองค์ประกอบทางเภสัชกรรมที่มีสารพาหะของออกซิเจนที่เสถียรต่อความร้อน
TH122386A (th) วิธีการสำหรับการเตรียมองค์ประกอบทางเภสัชกรรมที่มีสารพาหะของออกซิเจนที่เสถียรต่อความร้อน
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
Kim et al. A case of portal vein thrombosis in acute necrotizing pancreatitis treated with low-molecular-weight heparin
TH122386B (th) วิธีการสำหรับการเตรียมองค์ประกอบทางเภสัชกรรมที่มีสารพาหะของออกซิเจนที่เสถียรต่อความร้อน
HUANG Radiofrequency ablation for hepatocellular carcinoma: surgeon’s views

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: BING LOU WONG (US) , SUI YI KWOK (CN) , SZE HANG L

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: BILLION KING INTERNATIONAL LIMITED (CN)

B15K Others concerning applications: alteration of classification

Ipc: A61K 38/42 (2006.01), A61K 47/30 (2006.01), A61P 3

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]